Phase 1 has already been executed with the construction of temporary OPD, guest house and boundary wall and Phase 2 of the execution is being fast tracked
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Therapy recently approved in Canada under the brand name KORSUVA
The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022.
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
Subscribe To Our Newsletter & Stay Updated
